Bio-Rad Laboratories Inc. CI A (BIO) News
Filter BIO News Items
BIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BIO News Highlights
- BIO's 30 day story count now stands at 5.
- Over the past 13 days, the trend for BIO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about BIO are PAHC and ZBH.
Latest BIO News From Around the Web
Below are the latest news stories about BIO-RAD LABORATORIES INC that investors may wish to consider to help them evaluate BIO as an investment opportunity.
6 Cheap Healthcare Stock Picks With Room to Grow in 2024After an abysmal year for healthcare stocks, Wall Street is upbeat on Cigna, Humana, Bristol Myers, and three others. |
Bio-Rad (BIO) Faces Soft Industry-wide Demand, Macro WoesBio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses. |
Investors Aren't Entirely Convinced By Bio-Rad Laboratories, Inc.'s (NYSE:BIO) RevenuesWith a median price-to-sales (or "P/S") ratio of close to 3.9x in the Life Sciences industry in the United States, you... |
Why Is Phibro (PAHC) Up 13.6% Since Last Earnings Report?Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Why Is Zimmer (ZBH) Up 10.8% Since Last Earnings Report?Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Implied Volatility Surging for On Bio-Rad Laboratories (BIO) Stock OptionsInvestors need to pay close attention to Bio-Rad Laboratories (BIO) stock based on the movements in the options market lately. |
Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin PressureBio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses. |
Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 ViewThe deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance. |
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2023 Earnings Call TranscriptBio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2023 Earnings Call Transcript October 26, 2023 Bio-Rad Laboratories, Inc. misses on earnings expectations. Reported EPS is $2.33 EPS, expectations were $2.87. Operator: Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the Bio-Rad Third Quarter 2023 Financial Results Conference Call and Webcast. [Operator Instructions] And please […] |
Q3 2023 Bio Rad Laboratories Inc Earnings CallQ3 2023 Bio Rad Laboratories Inc Earnings Call |